drugset
drugset / Trial / NCT05567458

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

NCT05567458 ↗

Phase 2 Active not recruiting 94 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of luspatercept plus best supportive care (BSC) versus placebo plus BSC in participants who require regular red blood cell transfusions due to β-thalassemia.

Timeline

Start
2022-10-17
Primary completion
2025-08-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Luspatercept Protein / enzyme biologic — —

Indications

beta thalassemia